Friday May 10, 7:30 am Eastern Time
Press Release
SOURCE: Given Imaging, Ltd.
Given Imaging Announces Prominent Presence of M2A
Capsule at Digestive Disease Week 2002
- 48 Studies Involving Nearly 1,000 Patients to be Presented on Emerging Diagnostic Standard of
Care -
YOQNEAM, Israel, May 10 /PRNewswire-FirstCall/ -- Given Imaging, Ltd. (Nasdaq: GIVN - News) announced today that
leading gastrointestinal physicians will present 48 papers reviewing clinical results of M2A® capsule endoscopy at the Digestive
Disease Week (DDW) Conference, May 19 -22, in San Francisco.
Full details about Given's presence at DDW are provided on the Company's website at givenimaging.com. In
addition, the Company will sponsor a symposium: "Capsule Endoscopy in Clinical Practice" on Monday, May 20th from 6:00
pm to 8:00 pm at The Nikko Hotel.
The presentations, lectures and posters include data derived from studies showing the advantages of the M2A capsule
endoscope when compared to other imaging modalities in nearly 1,000 patients suffering from a broad range of gastrointestinal
diseases, such as, Inflammatory Bowel Disease, Crohn's Disease, Obscure Gastrointestinal Bleeding, Celiac Disease and
NSAID (Non-Steroidal Anti-Inflammatory Drugs) Associated Small Intestinal Ulcers.
"Capsule endoscopy is prompting extensive discussion among thought leaders who support more widespread use of the M2A
for a broad range of gastrointestinal disorders," Dr. Gavriel D. Meron, CEO and President of Given Imaging, Ltd. "This
extensive body of data presented at the most important GI medical meeting coupled with growing reimbursement coverage
underscores the value of the M2A as a diagnostic tool and accelerates acceptance of capsule endoscopy as a new standard of
care."
Among the highlights are the following abstracts:
* DDW-sponsored Topic Forum dedicated to the results of trials of
80 patients showing the advantage of capsule endoscopy in comparison to
push enteroscopy in obscure bleeding.
* State of the Art lecture given by Dr. Blair Lewis, the lead
investigator of the FDA first trials.
* First time released data of data regarding the advantages of capsule
endoscopy in the diagnosis of Crohn's disease, pediatrics and celiac
disease.
About M2A Capsule Endoscope
Given Imaging produces and markets the Given Diagnostic System, which features the M2A Capsule Endoscope, a
fundamentally new approach to examining the gastrointestinal tract. The system uses a disposable miniature video camera
contained in a capsule that is ingested by a patient and delivers high quality color images in a painless and noninvasive manner.
The test can be conducted while a patient continues normal daily activities. The system received clearance from the FDA in
August 2001 and received permission to affix the CE mark in May 2001. It is currently available in 33 countries worldwide,
including the USA, Canada, Europe, many countries in Latin America, and Israel. Many thousands of patients suffering from
diseases in the small intestine such as Crohn's, celiac disease, unexplained abdominal pain with diarrhea, polyposis, intestinal
tumors, iron deficiency anemia and obscure bleeding have already benefited from this innovative technology. For more
information, visit givenimaging.com.
About DDW
The DDW annual meeting is the premier international conference devoted to the science and practice of gastroenterology and
hepatology, hosting more than 15,000 clinicians, researchers and educators from all over the world and providing them with the
latest advances in gastroenterology and hepatology science and practice. The meeting is overseen by the DDW Council
comprised of representatives from the four DDW societies: the AGA, the American Association for the Study of Liver
Diseases, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. AGA
administers the meeting on behalf of the DDW Council.
This press release contains forward-looking statements, including projections about our business, within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the
future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," "intends" and words and terms of
similar substance used in connection with any discussion of future operating or financial performance identify such
forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results
could differ materially from our current expectations as a result of numerous factors, including but not limited to the following:
changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and
validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other
companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, and other risks
disclosed in our filings with the U.S. Securities Exchange Commission.
SOURCE: Given Imaging, Ltd. |
